Klemm Lars, Duy Cihangir, Iacobucci Ilaria, Kuchen Stefan, von Levetzow Gregor, Feldhahn Niklas, Henke Nadine, Li Zhiyu, Hoffmann Thomas K, Kim Yong-mi, Hofmann Wolf-Karsten, Jumaa Hassan, Groffen John, Heisterkamp Nora, Martinelli Giovanni, Lieber Michael R, Casellas Rafael, Müschen Markus
Leukemia and Lymphoma Program, Norris Comprehensive Cancer Center, University of Southern California, Los Angeles, CA 90027, USA.
Cancer Cell. 2009 Sep 8;16(3):232-45. doi: 10.1016/j.ccr.2009.07.030.
Chronic myeloid leukemia (CML) is induced by BCR-ABL1 and can be effectively treated for many years with Imatinib until leukemia cells acquire drug resistance through BCR-ABL1 mutations and progress into fatal B lymphoid blast crisis (LBC). Despite its clinical significance, the mechanism of progression into LBC is unknown. Here, we show that LBC but not CML cells express the B cell-specific mutator enzyme AID. We demonstrate that AID expression in CML cells promotes overall genetic instability by hypermutation of tumor suppressor and DNA repair genes. Importantly, our data uncover a causative role of AID activity in the acquisition of BCR-ABL1 mutations leading to Imatinib resistance, thus providing a rationale for the rapid development of drug resistance and blast crisis progression.
慢性髓性白血病(CML)由BCR-ABL1诱导产生,使用伊马替尼可有效治疗多年,直到白血病细胞通过BCR-ABL1突变获得耐药性并进展为致命的B淋巴细胞母细胞危象(LBC)。尽管其具有临床意义,但进展为LBC的机制尚不清楚。在此,我们表明LBC细胞而非CML细胞表达B细胞特异性突变酶AID。我们证明CML细胞中AID的表达通过肿瘤抑制基因和DNA修复基因的超突变促进整体遗传不稳定性。重要的是,我们的数据揭示了AID活性在导致伊马替尼耐药的BCR-ABL1突变获得过程中的因果作用,从而为耐药性的快速发展和母细胞危象进展提供了理论依据。